Amgen Highlights 26% Growth Drivers, IMDELLTRA Momentum and MariTide Potential

Amgen executives highlighted growth in key commercial products, advancement of late-stage pipeline programs, and an ongoing focus on profitability and cash returns at a Wells Fargo biotech and pharma discussion. The update is modestly positive for the company’s growth and capital-return outlook, though it provided no new financial figures, guidance changes, or clinical data.